Bayer, Versant and Fujifilm Cellular Dynamics, biotechnology companies have invested $250m in Century Therapeutics, a biotechnology company. The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. “Versant believes that allogeneic reagents represent the next wave of innovation in cell therapy and created Century to engineer truly off-the-shelf products to treat both hematologic and solid tumors. Today’s financing marks an important milestone in our effort to enable cell therapies to treat a much broader array of cancer patients.” Carlo Rizzuto, Versant partner and Century director.